VERENTA PHARMACEUTICALS
DEAD

Serial Number

78802619

Owner

Verenta Pharmaceuticals, LLC

Filing Date

Jan 30, 2006

Add to watchlist:

No watchlists yet
View on USPTO

VERENTA PHARMACEUTICALS Trademark

Serial Number: 78802619

VERENTA PHARMACEUTICALS is a trademark filed by Verenta Pharmaceuticals, LLC on January 30, 2006. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Verenta Pharmaceuticals, LLC

8527 Bluejacket Street
Lenexa, KS 66214

Entity Type: 16

Trademark Details

Filing Date

January 30, 2006

Registration Date

Not Registered

Published for Opposition

April 3, 2007

Goods & Services

Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Astringents; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting compounds that facilitate delivery of a wide range of pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with prodrugs, steroids, beta-agonists, anti- inflammatories or combinations thereof; Injectable pharmaceuticals for treatment of anaphylactic reactions; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations namely, anticoagulants; Pharmaceutical preparations namely, antidepressants; Pharmaceutical preparations namely, appetite suppressants; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Plant extracts for medical, veterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Synthetic peptides for pharmaceutical purposes; Unit dose capsules sold empty for pharmaceutical use; Vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Mar 5, 2008 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 5, 2008 ABN6
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jun 26, 2007 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 27, 2007 TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 27, 2007 TCCA
PUBLISHED FOR OPPOSITION
Apr 3, 2007 PUBO
NOTICE OF PUBLICATION
Mar 14, 2007 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 16, 2007 PREV
EXAMINER'S AMENDMENT ENTERED
Feb 16, 2007 XAEC
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 16, 2007 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 16, 2007 XAEC
EXAMINERS AMENDMENT E-MAILED
Feb 16, 2007 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 16, 2007 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 11, 2007 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jan 22, 2007 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 27, 2006 PREV
ASSIGNED TO LIE
Dec 27, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 8, 2006 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 8, 2006 XAEC
EXAMINERS AMENDMENT E-MAILED
Dec 8, 2006 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 8, 2006 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Dec 8, 2006 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 8, 2006 CNSA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Nov 19, 2006 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Oct 27, 2006 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 12, 2006 PREV
ASSIGNED TO LIE
Oct 6, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 4, 2006 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 4, 2006 XAEC
EXAMINER'S AMENDMENT ENTERED
Oct 4, 2006 XAEC
EXAMINERS AMENDMENT E-MAILED
Oct 4, 2006 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 4, 2006 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 27, 2006 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 14, 2006 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 14, 2006 TROA
NON-FINAL ACTION E-MAILED
Jul 24, 2006 GNRT
NON-FINAL ACTION WRITTEN
Jul 24, 2006 CNRT
ASSIGNED TO EXAMINER
Jul 19, 2006 DOCK
NOTICE OF DESIGN SEARCH CODE MAILED
Feb 4, 2006 MDSC
NEW APPLICATION ENTERED
Feb 3, 2006 NWAP